Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers Review uri icon


MeSH Major

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Drug Delivery Systems
  • Hypertension
  • Renin-Angiotensin System


  • Agents that counteract the negative impact of the renin-angiotensin-aldosterone system (RAAS) are effective antihypertensives and reduce the risk of developing Type 2 diabetes. Contrary to common perception, angiotensin-converting enzyme inhibitors do not share the apparent benefit of angiotensin II receptor blockers (ARBs) in reducing risk of cardiovascular-disease outcomes, particularly stroke, in randomised clinical trials. RAAS agents, especially ARBs, are well tolerated. Use of ARBs alone or in combination with other classes of antihypertensive agents to lower blood pressure and/or medications to control other conditions (e.g., insulin sensitivity) reduces risk of cardiovascular disease outcomes and Type 2 diabetes with excellent tolerability. Selected issues related to use of RAAS agents as antihypertensive therapies (e.g., Type 2 diabetes, global risk management, multiple drug therapy and coronary heart disease) are addressed.

publication date

  • November 2005



  • Review



  • eng

Digital Object Identifier (DOI)

  • 10.1517/14728214.10.4.729

PubMed ID

  • 16262560

Additional Document Info

start page

  • 729

end page

  • 45


  • 10


  • 4